date:Oct 26, 2018
have clarity when it comes to drugs, though. As for exports to US or other regulated markets, this can be an advantage and hence the increased cost in manufacturing can be justified. But for India, we still need to define the overall process and advantage to the companies before we adapt these standards, Kulkarni said.
Meanwhile, John Atwater, senior director, verification program, USP; Dr Nandu Sarma, director, dietary supplement and herbal medicine, USP; and Gabriel Glancaspro, vice-president